Oryzon Genomics S.A.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (NCT05546580) | Oryzon Genomics S.A. | 2022-11-14 |
| Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population (NCT04932291) | Oryzon Genomics S.A. | 2021-03-26 |
| Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease (NCT03867253) | Oryzon Genomics S.A. | 2019-05-16 |
Track Oryzon Genomics S.A. automatically
Every clearance here is in the API, with alerts when new ones post.